COL5A2 作为胃癌和肾转移的潜在临床生物标志物。

COL5A2 as a potential clinical biomarker for gastric cancer and renal metastasis.

机构信息

Emergency Department, Weifang People's Hospital.

Anaesthesiology Department, Weifang Maternal and Child Health Care Hospital, Weifang, Shandong Province, China.

出版信息

Medicine (Baltimore). 2021 Feb 19;100(7):e24561. doi: 10.1097/MD.0000000000024561.

DOI:10.1097/MD.0000000000024561

PMID:33607786

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7899835/

Abstract

BACKGROUND

Gastric cancer, characterized by insidious onset and multiple metastasis, is almost incurable and has poor prognosis, and also one of the leading causes of treatment failure and death in patients with gastric cancer (GC). However, the prognosis of collagen type V alpha2 chain (COL5A2) in GC and renal metastasis is unknown.

METHODS

Recruited 148 patients who underwent GC. The diagnosis of GC was confirmed by ultrasound imaging and pathological examination. Immunohistochemistry and RT-qPCR were performed to exam the expression level of COL5A2. The statistical methods included Pearson chi-square test, Spearman-rho correlation test, univariate and multivariate cox regression analysis. Finally, this research constructed receiver operating characteristic (ROC) curves and applied the area under the curve (AUC).

RESULTS

Based on Pearson's chi-square test, Spearman-rho test, and univariate/multivariate cox regression, pathologic grade (P < .001), renal metastasis (P < .001) and staging (P < .001) were significantly related to COL5A2. And COL5A2 expression (hazard ratio [HR]: 18.834, P < .001) is an independent risk factor of GC. The AUC was used as the degree of confidence in judging each factor: COL5A2 (AUC = 0.878, P < .001), COL1A1 (AUC = 0.636, P = .006), COL1A2 (AUC = 0.545, P = .368), and COL3A1 (AUC = 0.617, P = .019). Through the ROC result, COL5A2 had more advantage as a biomarker for GC than other collagens.

CONCLUSIONS

COL5A2 gene expression level might be a risk factor for GC. COL5A2 has a strong correlation with the prognosis of the disease.

摘要

背景

胃癌具有隐匿性发病和多发性转移的特点，几乎无法治愈，预后不良，也是导致胃癌（GC）患者治疗失败和死亡的主要原因之一。然而，COL5A2 基因在 GC 和肾转移中的表达水平及其预后意义尚不清楚。

方法

招募了 148 例接受 GC 治疗的患者。通过超声成像和病理检查确诊为 GC。采用免疫组化和 RT-qPCR 检测 COL5A2 的表达水平。统计方法包括 Pearson 卡方检验、Spearman-rho 相关检验、单因素和多因素 Cox 回归分析。最后，构建了受试者工作特征（ROC）曲线并应用曲线下面积（AUC）。

结果

基于 Pearson 卡方检验、Spearman-rho 检验和单因素/多因素 Cox 回归分析，病理分级（P<0.001）、肾转移（P<0.001）和分期（P<0.001）与 COL5A2 显著相关。COL5A2 表达（风险比[HR]：18.834，P<0.001）是 GC 的独立危险因素。AUC 被用作判断每个因素的置信度：COL5A2（AUC=0.878，P<0.001）、COL1A1（AUC=0.636，P=0.006）、COL1A2（AUC=0.545，P=0.368）和 COL3A1（AUC=0.617，P=0.019）。通过 ROC 结果，COL5A2 作为 GC 生物标志物的优势强于其他胶原。